Clinical Trials Resource Center

New Medical Therapies™

Phenylketonuria

Patient Medical Areas

August 9, 2010

BioMarin released positive preliminary results from a phase II trial of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria. This open-label, multi-center study enrolled 23 adults who were placed in a series of dose-escalating cohorts starting from 0.001 mg/kg. The primary endpoint was to evaluate the effect of PEG-PAL on blood Phe concentrations. Seven subjects received at least 1 mg/kg/week for at least four weeks in several different dosing frequencies (up to three times per week). Of these, six had Phe levels below 600 umol/L for at least three weeks and up to three months. Their baseline Phe levels were reduced from a median of 1,293 umol/L to a median of 527 umol/L, representing an approximate 60% reduction in blood Phe. Two subjects had blood Phe levels documented below 5 umol/L. Injection site reaction was the most common treatment emergent adverse event.

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.